Current and investigational drugs in early clinical development for portal hypertension
Frontiers in Medicine, 2022 IntroductionThe development of portal hypertension leads to a majority of complications associated with chronic liver disease. Therefore, adequate treatment of portal hypertension is crucial in the management of such patients.
Sasan Sakiani +2 more
doaj +1 more source
Profile of clindamycin phosphate 1.2%/benzoyl peroxide 3.75% aqueous gel for the treatment of acne vulgaris. [PDF]
, 2015 Acne vulgaris is a common and chronic skin disease, and is a frequent source of morbidity for affected patients. Treatment of acne vulgaris is often difficult due to the multifactorial nature of this disease.
Eichenfield, Lawrence F, Nguyen, Tuyet A
core +2 more sources
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Journal of Experimental Pharmacology, 2021 Giacomo Grassi, Chiara Cecchelli, Luisa Vignozzi, Silvia Pacini Neuroscience Department, Brain Center Firenze, Florence, ItalyCorrespondence: Giacomo GrassiBrain Center Firenze, Viale Belfiore 36, Florence 50144, ItalyEmail giacomograssimd@gmail ...
Grassi G +3 more
doaj
Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease
Pharmaceuticals, 2021 Alzheimer’s disease (AD; progressive neurodegenerative disorder) is associated with cognitive and functional impairment with accompanying neuropsychiatric symptoms.
Barbara Miziak +2 more
doaj +1 more source
Compassionate Drug Use – Time Arising for a New Law in Bulgaria in the Era of COVID-19 [PDF]
Folia Medica, 2020 Introduction: Despite clinical trials, there are still no approved specific therapies or any vaccine against COVID-19. The only option available is using investigational drugs for compassionate use.
Nigyar Dzhafer, Jannis V. Papathanasiou
doaj +3 more sources
Sometimes the Silence Can Be like the Thunder: Access to Pharmaceutical Data at the FDA [PDF]
, 2006 Those committed to the free exchange of scientific information have long complained about various restrictions on access to the FDA\u27s pharmaceutical data and the resultant restrictions on open discourse.
Ankelhed, Daniel +2 more
core +2 more sources
Medical treatment of ascites in cirrhosis [PDF]
, 1993 Medical treatment of cirrhotic ascites is essentially supportive, dictated by the patient's discomfort, impaired cardiovascular or respiratory function and potential for infection. Treatment of ‘simple’ ascites (moderate fluid accumulation, serum albumin
Alexander L. Gerbes +41 more
core +1 more source
Benefit assessment of extended dosing in cancer patients after their withdrawal from clinical trials
Frontiers in Pharmacology, 2023 Background: Clinical trials have been widely recognized as an effective treatment approach by physicians and cancer patients alike. Physicians’ evaluations suggest that many patients are likely to continue experiencing benefits from extended dosing of ...
Feng Yang +4 more
doaj +1 more source
Standard care and investigational drugs in the treatment of myelofibrosis
Drugs in Context, 2019 Myelofibrosis (MF) is a heterogeneous disorder characterized by splenomegaly, constitutional symptoms, ineffective hematopoiesis, and an increased risk of leukemic transformation.
Daniela Barraco +2 more
doaj +1 more source
Enhancing Clinical Trials Through Synergistic Gamma Power Analysis
Frontiers in Psychiatry, 2020 While the etiology of many neuropsychiatric disorders remains unknown, increasing evidence suggests that aberrant sensory processing plays a central role.
Sokichi Honda +3 more
doaj +1 more source